secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070305
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q1 2025 net loss of $10.6M; cash runway extended to 2028
--------------------------------------------------------------------------------

- Net loss of $10.6M vs $16.6M in Q1 2024; R&D expenses down to $7.7M from $14.7M.
- Cash and investments of $78.5M at March 31, 2025; operating runway now projected into 2028.
- Initiated Phase 1 first-in-human study of AN2-502998 for chronic Chagas disease; expected completion in H2 2025.
- Plans to initiate Phase 2 study of epetraborole in melioidosis; advancing epetraborole for NTM lung disease non-dilutive.
- Oncology pipeline advancing; first compound(s) expected to enter development in 2025 within current cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025070305/0000950170-25-070305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025070305/antx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer